| Literature DB >> 24570766 |
Jeremy Simcock1, Barnaby C H May2.
Abstract
OBJECTIVE: Split skin graft reconstruction of scalp defects often leaves an obvious contour defect. Here, we aimed to demonstrate the use of a decellularized extracellular matrix biomaterial, termed ovine forestomach matrix (OFM), as a substrate for split-thickness skin grafts (STSGs) for scalp reconstruction.Entities:
Keywords: biomaterial; carcinoma; ovine forestomach matrix; reconstruction; split-thickness graft
Year: 2013 PMID: 24570766 PMCID: PMC3922230
Source DB: PubMed Journal: Eplasty ISSN: 1937-5719
Inclusion and exclusion criteria
| Inclusion criteria | Exclusion criteria |
|---|---|
| >18 years old | Any cutaneous malignancies with metastatic disease |
| At least 1 nonmelanoma skin cancer without metastatic disease | Diagnosed with malignant melanoma |
| Malignancies that require full-thickness excision | Systemic malignancy |
| Postexcision wounds that would normally be reconstructed with a split skin graft | Under suspicion of metastatic disease |
| Pregnant or lactating | |
| Compliant | Clinically significant cardiac, pulmonary, renal, hepatic, neurologic, and/or immune dysfunction that may affect wound healing |
| Competent | |
| Tumor located on the scalp, neck, or upper limbs | Known allergy to collagen or ovine (sheep) materials; any previous reaction to a collagen product |
| Family or personal history of severe allergies (including asthma, hay fever, and atopic dermatitis) | |
| Allergies to foods, especially meat products | |
| Unable to remain in study for 6 mo | |
| Diabetes mellitus | |
| Declined, unable, or unwilling to make informed consent | |
| Not fluent in English or Maori—requires interpreter | |
| Religious or ethical objections to sheep-derived product | |
| Previous radiotherapy at the defect site | |
| Immunosuppressant medication (prednisone >5 mg/d or equivalent) |
Figure 1Representative images of the tumor resection and single-stage split-thickness grafting. (a) Excisional defect following tumor excision and meshed OFM prior to rehydration. (b) Rehydrated OFM cut to size and placed within the defect to conform to the underlying periosteum. (c) Meshed STSG in contact with the underlying OFM. (d) Secondary dressings secured to the perimeter of the excision.
Summary of participant details and outcomes
| Participant | Sex | Age | Tumor location | Age, mo | Type | Area, cm2 |
|---|---|---|---|---|---|---|
| B001 | Male | 83 | Left vertex scalp | 4 | SCC | 1.5 |
| B002 | Male | 83 | Left anterior scalp | 9 | BCC | 1.2 |
| B003 | Male | 73 | Vertex scalp | 8 | Previous SCC | 16.0 |
| B004 | Male | 81 | Left vertex scalp | 2.5 | SCC | 2.9 |
| B005 | Male | 61 | Left vertex scalp | 6 | SCC | 4.6 |
Figure 2Representative images of the study participants B001 (2.A., 2.B., 2.C.), B002 (2.D., 2.E., 2.F.), B003 (2.G., 2.H., 2.I.), B004 (2.J., 2.K., 2.L.), and B005 (2.M., 2.N., 2.O.), prior to tumor excision (2.A., 2.D., 2.G., 2.J., 2.M.) and 1 week following surgery (2.B., 2.E., 2.H., 2.K., 2.N.). Surgical site following healing; 2.C., 40 weeks; 2.E., 16 weeks; 2.I., 16 weeks; 2.L., 4 weeks (prior to reexcision); 2.O., 4 weeks (prior to reexcision).
Figure 3(a) Gomori's Trichome stain of the excised graft from B004, 4 weeks postgraft (4× magnification). Arrows indicate the intact fragments of OFM. Insert shows a 40× magnification of the area indicated by the black square. (b) CD34 immunohistochemistry of the excised graft from B004, 4 weeks postgraft (4× magnification). Insert shows a 40× magnification of the area indicated by the black square.